Show simple item record

dc.contributor.authorSakthivel, Priya
dc.contributor.authorGereke, Marcus
dc.contributor.authorBreithaupt, Angele
dc.contributor.authorFuchs, Dietmar
dc.contributor.authorGigliotti, Luca
dc.contributor.authorGruber, Achim D
dc.contributor.authorDianzani, Umberto
dc.contributor.authorBruder, Dunja
dc.date.accessioned2014-07-18T09:38:37Z
dc.date.available2014-07-18T09:38:37Z
dc.date.issued2014
dc.identifier.citationAttenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells. 2014, 9 (7):e100970 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid25029240
dc.identifier.doi10.1371/journal.pone.0100970
dc.identifier.urihttp://hdl.handle.net/10033/323399
dc.description.abstractInducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8+ T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects.
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen
dc.titleAttenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells.en
dc.typeArticleen
dc.identifier.journalPloS oneen
refterms.dateFOA2018-06-12T22:57:13Z
html.description.abstractInducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8+ T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects.


Files in this item

Thumbnail
Name:
Sakthivel et al_final.pdf
Size:
7.144Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record